Skip to main content

Canopy Growth Corp (WEED-T) Quote

Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 20.08
Day High 20.99
Open:20.08
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Canopy Growth Reports Second Quarter Fiscal 2020 Financial Results
- PR Newswire - Thu Nov 14, 5:30AM CST
PR Newswire - CMTX
Thu Nov 14, 5:30AM CST
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) today announced its financial results for the second quarter ended September 30, 2019. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. This press release is intended to be read in conjunction with the Company's Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis for the three and six months ended September 30, 2019, which will be filed on SEDAR (www.sedar.com) and will be available at www.canopygrowth.com.
Canopy Growth Reports Second Quarter Fiscal 2020 Financial Results
- PR Newswire - Thu Nov 14, 5:30AM CST
PR Newswire - PRNW
Thu Nov 14, 5:30AM CST
SMITHS FALLS, ON , Nov. 14, 2019 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) today announced its financial results for the second quarter ended September 30, 2019 . All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. This press release is intended to be read in conjunction with the Company's Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis for the three and six months ended September 30, 2019 , which will be filed on SEDAR ( www.sedar.com ) and will be available at www.canopygrowth.com . 
Regulators Take Further Steps to Expand the Medical CBD Industry
- PR Newswire - Wed Nov 13, 8:00AM CST
PR Newswire - CMTX
Wed Nov 13, 8:00AM CST
The medical cannabis industry continued to progress after the National Health Services in England and Wales recently decided to approve cannabis-based medicines. Specifically, three treatments using medicinal cannabis were approved by the National Institute for Health and Care Excellence (NICE). As such, NICE noted that these cannabis-based medicines will be restricted to the treatment of only one of two rare forms of childhood epilepsy, multiple sclerosis, and chemotherapy-induced nausea. The institute also noted that all marijuana-based medications must be prescribed by specialist doctors. And an institute spokesman said that the recommendations could immediately be applied for England and Wales, with Northern Ireland expected to consider their use on a case-by-case basis, according to the New York Times. However, the rules do not apply in Scotland, which has its own healthcare guidelines. Generally, the approval by the constituent countries of the U.K. marks another major milestone within the cannabis industry. And England and Wales now join a handful of other international regions that have decided to move towards legalizing medical cannabis. For instance, major countries such as Australia, Canada, Colombia, France, Germany, Italy, Spain, and parts of the U.S. have all moved to adopt some sort of medical cannabis legislation. However, to note, most countries tend to have varying regulations on which specific ailments cannabis is eligible to treat. Nevertheless, as clinical trials continue to advance, industry experts believe that cannabis will become an important alternative treatment for numerous ailments. And according to data compiled by Fortune Business Insights, the global cannabis market was valued at USD 10.6 Billion in 2018. By 2026, the market is expected to reach USD 97.35 Billion while exhibiting a CAGR of 32.92% during the forecast period from 2019 to 2026. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aphria Inc. (NYSE: APHA) (TSX: APHA), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB)
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 20.08 +1.05% increase
on 11/15/19
Period Open:26.53
Price movement based on the high, low and last over the given period.
29.34 -30.85% decrease
on 10/28/19
-6.24 (-23.52%) decrease
since 10/15/19
3-Month 20.08 +1.05% increase
on 11/15/19
Period Open:36.41
Price movement based on the high, low and last over the given period.
38.33 -47.06% decrease
on 09/18/19
-16.12 (-44.27%) decrease
since 08/15/19
52-Week 20.08 +1.05% increase
on 11/15/19
Period Open:46.44
Price movement based on the high, low and last over the given period.
70.98 -71.41% decrease
on 04/30/19
-26.15 (-56.31%) decrease
since 11/15/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).